QH-103 Cell Therapy

N/A

Report date: 2026/05/02 20:00:18

Base Information

Drug NameQH-103 Cell Therapy
Drug Alias NameQH103 Cell TherapyCD19 CAR-γδT Cell TherapyQH-103
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Universal CAR-TCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy +[4] 
Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsMyelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseAntiphospholipid SyndromeAutoimmune Diseases +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Qinghui Liannuo Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesThe Third Affiliated Hospital Of Beijing UniversityThe Second Affiliated Hospital Of Fujian Medical UniversityAnhui Provincial Hospital +[6] 
Inactive CompaniesN/A
Active IndicationsMyelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseAntiphospholipid SyndromeAutoimmune Diseases +[15] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A